EOLS - Jeuveau Forward Price-to-Revenue Multiple

Corporate emblem and logo of Evolus, Inc. (EOLS)

Amid the implementation of AI platforms to automate customer service in aesthetic medicine, the expected P/S dynamics of Evolus, Inc. (EOLS) objectively capture the asset's market value. The value 1.40 serves as the baseline valuation metric. However, the risk of declining consumer spending and price wars are squeezing margins, while the brand's success relies on millennial loyalty and the reliability of overseas supplies.

EOLS Evolus Inc: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/14/2026

Analytical breakdowns for Evolus, Inc.

- market price and analyst price targets:
Price Chart Evolus|EOLS - Price Target Chart
- market capitalization statistics:
Market Valuation Evolus Corp|EOLS - Enterprise Value
- business book valuation details:
Net Assets per Single Share Evolus|EOLS - Book Valuation of Business|Market Cap to Net Assets Ratio evolus.com|EOLS - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital Evolus, Inc.|EOLS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Evolus, Inc.|EOLS - Company Aggregate Debt|Debts to Book Capitalization Evolus Corp|EOLS - Company Long-Term Liabilities|Company Current Liabilities Evolus|Quick Ratio evolus.com
- business earnings and investment ratios data:
EOLS - Company Net Income|Expected Profit Evolus, Inc.|EOLS - Market Cap to Earnings|Future Price to Earnings Jeuveau|EOLS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Evolus Corp|EOLS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Evolus|EOLS - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months evolus.com|EOLS - Earnings per share increase in current year|Earnings growth forecast for next year Evolus, Inc.
- sales volume and revenue indicators:
EOLS - Company Total Revenue|Projected Sales Volume Evolus|EOLS - P/S Multiple|Forward Price-to-Revenue Multiple Evolus Corp
Fundamental company valuation:Evolus EOLS
Product sample of Evolus, Inc.

Evolus, Inc. is scaling its medical record automation software and testing physical robots as it moves toward the systemic implementation phase of these technologies. The ratio of market capitalization to projected revenue measures the premium for future growth; therefore, the forward P/S multiple on GURU.Markets allows an investor to determine the extent of the overpayment for the company's status as a defensive asset or to identify an undervaluation of the business.

Competitors of Evolus, Inc. (EOLS)

Price-to-Projected Revenue Ratio HCA Healthcare HCA|Tenet Healthcare Corp - Price-to-Projected Revenue Ratio|FMS: Forward Price-to-Revenue Multiple|SOLV - Forward P/S Multiple|Encompass Health (EHC) - Price-to-Projected Revenue Ratio|UHS - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple DVA|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|Market Cap to Expected Sales Ratio Surgery Partners Group|Price-to-Projected Revenue Ratio Premier, Inc. PINC|EYE: Market Cap to Projected Revenue|Progyny - Forward P/S Multiple|Ardent Health (ARDT) - Forward Price-to-Revenue Multiple|SEM (Select Medical Corp) - Forward Price-to-Revenue Multiple|ASTH - Market Cap to Expected Sales Ratio|MD (Pediatrix Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio US Physical Therapy Inc USPH|Price-to-Projected Revenue Ratio The Pennant Group (PNTG)|ORGO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Nutex Health Corp NUTX|Auna Corp - Price-to-Projected Revenue Ratio|SBC - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio chs.net CYH|SKIN (beautyhealth.com) - Forward Price-to-Revenue Multiple|MDWD: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Biote Corp|JYNT: Forward Price to Sales|Forward P/S Multiple DCGO|PIII - Market Cap to Future Revenue Ratio|Forward P/S Multiple GANX (Gain Therapeutics)|Forward P/S Multiple EUDA Health Holdings EUDA|BMGL: Forward Price-to-Revenue Multiple|CollPlant Biotechnologies - Price to Expected Revenue Ratio|Cuprina Holdings (Cayman) Ltd (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple concordmedical.com|AMS (American Shared Hospital Services) - Forward P/S Multiple|Market Cap to Future Revenue Ratio MEDIROM Healthcare Group Inc. MRM|Price-to-Projected Revenue Ratio Avalon GloboCare (ALBT)|DIH Group - Market Cap to Projected Revenue|Longevity Health Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NIVF (newgenivf.com)|ATI Physical Therapy Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio CareMax Inc.|KDLY (Kindly MD Corp) - Forward Price-to-Revenue Multiple|MODV (ModivCare Corp) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Novo Integrated Sciences|Market Cap to Future Revenue Ratio SunLink Health Systems, Inc SSY|Price-to-Projected Revenue Ratio IMAC Holdings (BACK)